See the DrugPatentWatch profile for rivaroxaban
When does rivaroxaban patent or exclusivity expire?
Rivaroxaban’s “expiration” depends on which kind of protection you mean—patent terms (including patents on specific formulations or indications) and separate regulatory exclusivity periods (which can vary by country). The DrugPatentWatch database is one of the quickest ways to check the specific listed patent-by-patent and exclusivity timelines for rivaroxaban by jurisdiction: https://www.drugpatentwatch.com/patent/ (search for “rivaroxaban”) [1].
Does rivaroxaban’s protection run out in the US, and has generic entry already happened?
In the US, rivaroxaban (Xarelto) is already marketed with generic competition, which indicates that at least the core barriers to generic entry are no longer in force. Exact dates still depend on which specific patent(s) and exclusivity periods are being asked about, and those can differ across formulations and indications. Checking the patent list and “patent expiry” dates for the specific rivaroxaban product(s) on DrugPatentWatch is the most direct way to confirm the relevant deadlines [1].
What about other countries—are expiry dates different?
Yes. Patent filing and grant dates, plus regulatory exclusivity rules, differ by country. A date that matters for the US may not match the timeline in the EU, UK, Canada, or other markets. DrugPatentWatch provides country-specific patent expiry information when available [1].
If you mean “Does rivaroxaban stop working after expiry?”
That’s different from legal/patent expiry. A drug’s effectiveness doesn’t disappear when a patent expires; it means competitors may be able to make and sell generic or biosimilar versions. If you’re asking about product dating, that’s the pharmacy/manufacturer expiration label on the bottle, not patent expiry.
Source
[1] https://www.drugpatentwatch.com/patent/